ResearcherKanazawa UniversityActive in the last 2 years

Masahiro Uehara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9874-2672. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer. Co-author DOI 10.20517/cdr.2023.84 ↗
Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer. Co-author DOI 10.1111/cas.14668 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Tomoharu Miyashita · 2 shared papers, 2020–2024 · strength 0.37
- Paper Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer. DOI 10.20517/cdr.2023.84 ↗
- Paper Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer. DOI 10.1111/cas.14668 ↗
Toshinari Minamoto Md · 2 shared papers, 2020–2024 · strength 0.37
- Paper Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer. DOI 10.20517/cdr.2023.84 ↗
- Paper Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer. DOI 10.1111/cas.14668 ↗
Takeo Shimasaki · 1 shared paper, 2024 · strength 0.24
- Paper Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer. DOI 10.20517/cdr.2023.84 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.